IMR Press / EJGO / Special Issues / breast_cancer

Prognosis and Treatment of Breast Cancer

Submission deadline: 30 June 2022
Special Issue Editors
Akshara Singareeka Raghavendra, MD
Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: Pathways to overcome hormone therapy resistance; Prognostic factors; Use of multimodality imaging techniques for early detection and treatment of breast cancer
Special Issue Information

Dear Colleagues,

Prognostic and Predictive factors influencing breast cancer: It is now well established that women with early stage disease may have micro metastases, thus putting them at risk of developing overt metastases. This has been the main justification for using adjuvant systemic therapy in early stage breast cancer patients. However, many patients receive this therapy with little benefit and substantial toxicity, while others who do not receive adjuvant therapy still do well and show no evidence of recurrence or metastases. This highlights the need to optimize the use of adjuvant therapy based on individual prognostic and predictive factors. Prognostic factors provide information on clinical outcome at the time of diagnosis, independent of any therapy.

New efforts are being made in the area of breast cancer prognosis and detection. Broadening this effort to predict the likelihood of tumor spread to a specific location may improve our current approach to the treatment or surveillance of metastasis/recurrence and to its early detection.

The scope of this issue is to cover recent perspectives on breast cancer prognosis and the predictive factors involved, with an emphasis on finding robust and contemporary prognostic models for overall survival in early stage and metastatic breast cancer patients.

Treatment strategies for early and advanced stages of breast cancer: Improved screening techniques have led to increased diagnosis of early stage breast cancers, including stages I-III. Patients with early stage breast cancer generally have a good prognosis, but there is still a risk of disease recurrence and breast cancer-related death.

The scope of this issue includes the evaluation of treatment patterns and outcomes in patients with hormone receptor positive, HER2 negative, triple negative biomarkers in early stage breast cancer, locally advanced breast cancer, and metastatic breast cancer. This issue will also describe current treatment patterns and their effectiveness, unusual responders to treatment, and the evaluation of genomic alterations and their correlation with patient outcomes. We aim to assess different neoadjuvant and metastatic chemotherapy regimens and their effectiveness in terms of impact on overall or progression-free survival.

Dr. Akshara Singareeka Raghavendra

Guest Editor

Keywords
Staging
Chemotherapy
Metastasis
Biomarker
Overall survival
Progression-free survival
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top